ExcelMab Inc. announced today that the company's proprietary CD20×CD3 bispecific antibody drug EX103 injection has been administered to the first patient in the Phase I clinical trial under the leadership of Professor Qi Junyuan from the Hospital of Hematology, Institute of Hematology, Chinese Academy of Medical Sciences and with the joint efforts of experts and teachers, and the subject is in good condition.

The trial aims to evaluate the safety, tolerability and pharmacokinetic characteristics of EX103 injection in patients with relapsed or refractory CD20-positive non-Hodgkin's lymphoma, and to explore its antitumor activity initially.

About EX103

EX103 injection is a bispecific antibody targeting CD20 and CD3 for the treatment of relapsed or refractory CD20-positive non-Hodgkin's lymphoma,  and is the first CD20/CD3 BsAb that was developed by a Chinese company to enter clinical trials. Compared with international molecules in development with the same target, EX103 injection has remarkable efficacy and good safety, and its cytokine release level is only one-sixth of international similar products, which greatly improves the safety and treatment window and is expected to become the best among similar molecules in the world.